iRhythm Technologies‘ Zio ECG patch won praises from NIH Director Dr. Francis Collins this week for its ability to aid in the detection of atrial fibrillation. In an NIH Director blog post, Dr. Collins warned that while the dangers of atrial fibrillation are known, many individuals do not know they have atrial fibrillation and therefore […]
NinePoint Medical said earlier this month that it appointed Eman Namati as its new president and chief executive officer, succeeding Christopher von Jako who will remain on the company’s board of directors. Namati joined NinePoint Medical at its inception in 2010 as a technical co-founder, and operated as R&D VP for the past four years, […]
Abbott (NYSE:ABT) touted two-year data yesterday from its trial designed to compare the company’s HeartMate 3 left ventricular assist device to its HeartMate 2 device in patients with advanced heart failure. Data from the study were published in The New England Journal of Medicine and presented at the American College of Cardiology’s 67th Annual Scientific Session. More […]
iRhythm Technologies yesterday increased the scale of its initial public offering, pricing the flotation above its prior range at $17 per share and increasing the number of shares on offer. Earlier this month iRhythm said it planned to float 5.35 million shares priced between $13 and $15 apiece. Yesterday the San Francisco-based company added nearly 1.1 million shares, for a […]
iRhythm Technologies last week set the terms on its forthcoming initial public offering, saying it plans to float 5.35 million shares priced between $13.00 and $15.00 apiece. At the midpoint, the IPO would fetch $74.9 million. San Francisco-based iRhythm has said it plans to use the proceeds to expand the commercial and clinical footprint of its Zio wearable cardiac […]
iRhythm Technologies last week registered for an initial public offering worth $86 million it plans to use to expand the commercial and clinical footprint of its Zio wearable cardiac monitor. San Francisco-based iRhythm won 510(k) clearance for the Zio device in 2009. It’s designed to be worn for 14 days to log heartbeat data; the company […]
Biolase (NSDQ:BIOL) said earlier this month that CEO Jeffery Nugent has resigned from both his position as CEO and the board of directors, effective July 12, to be replaced by Harold Flynn. Irvine, Calif.-based Biolase picked up Flynn, the former president of Zimmer Dental (NYSE:ZMH), in May to replace Nugent, who the company said had stepped in to […]
Digital health is all the rage in Silicon Valley, especially as consumer technology’s biggest players are getting more interested in tracking health and fitness. But for companies like iRhythm, the health side of the equation comes first.
Remote monitoring startup iRhythm touted a new $17 million Series E funding round in support of its wearable devices, saying it plans to pursue efforts in commercialization, marketing and clinical studies.
The San Francisco company offers continuous cardiac monitoring with its FDA-cleared Zio wearable device and accompanying software. The system is designed to log data on patients’ heart rhythms, then process and analyze the data to kick out a report for physicians.